Table 2. Agreement between assays on matched samples from patients with BC

Agreement between 28-8 (TC ≥ 1%) and 22C3 (CPS ≥ 1) (N = 18)a
28-8 as reference22C3 as reference
OPA (n/N)94 (17/18)
PPA (n/N)100 (6/6)86 (6/7)
NPA (n/N)92 (11/12)100 (11/11)
Agreement between 22C3 (CPS ≥ 1) and SP142 (IC ≥ 1%) (N = 33)b
22C3 as referenceSP142 as reference
OPA (n/N)64 (21/33)
PPA (n/N)86 (12/14)55 (12/22)
NPA (n/N)47 (9/19)82 (9/11)
  • aData are presented for 28-8 and 22C3 tests on matched samples with 22C3 tests performed between Q1 2019 and Q4 2019; bData are presented for 22C3 and SP142 tests on matched samples with 22C3 tests performed between Q1 2019 and Q4 2019. N, total number of samples; n, number of samples with the same results with the 2 tests; NPA, negative percentage agreement; PPA, positive percentage agreement.